Infinity Pharmaceuticals has reported promising data from an ongoing Phase I trial of its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma ‘IPI-145’ in patients with relapsed/refractory T-cell lymphoma.
The trial included 30 patients in the safety population, of which 26 were evaluable for clinical activity and had advanced disease, with a median of five prior systemic therapies (range: 1 – 11) and a median of one month from last therapy to first dose on study (range: 0.2 – 12).
Go deeper with GlobalData
In the preliminary data, IPI-145 showed that it is clinically active in patients with T-cell lymphoma, with an overall response rate of 38%, including one complete response and nine partial responses among 26 patients evaluable for response.
The company said that among the 11 patients with peripheral T-cell lymphoma (PTCL) evaluable for activity, IPI-145 led to one complete response and five partial responses, for an overall response rate (ORR) of 55%, while in the remaining 15 patients with cutaneous T-cell lymphoma (CTCL) evaluable for activity, the drug candidate led to four partial responses, for an ORR of 27%.
Infinity president of R&D Julian Adams said the clinical data for IPI-145 in patients with T-cell lymphoma underscore the potential of IPI-145 to treat a broad range of blood cancers.
"IPI-145 has already shown clinical activity in indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia, and Infinity is advancing IPI-145 into late-stage development in these two hematologic malignancies," Adams said.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData"These data in patients with T-cell lymphoma help further our understanding of the clinical potential of IPI-145 in additional indications and may help to guide our future development plans."
According to the company, IPI-145 was generally well tolerated, with the majority of patients receiving IPI-145 dosed at 75mg twice daily (BID) and the most common grade 3 side effects were increases in ALT or AST (two liver enzymes), rash and fatigue, while one patient had grade 4 ALT or AST increases.
As part of the DUETTS programme, a worldwide investigation of IPI-145 in blood cancers, Infinity is currently enrolling patients in DYNAMO, a Phase II monotherapy study designed to evaluate the safety and efficacy of IPI-145 in patients with refractory indolent non-Hodgkin lymphoma and DUO, a Phase III monotherapy study designed to evaluate the safety and efficacy of IPI-145 in patients with relapsed/refractory chronic lymphocytic leukemia.
Image: Lymphoma is the most common form of haematological malignancy. Photo: courtesy of freedigitalphotos.net.
